Cancer Research · 2005 · 833 citations · 15 references
MedicineImmunologyOncologyCancer ImmunologyCellular ImmunologyTumor ImmunologyCytokine BiologyCytokines In Tumor ImmunityKidney CancerMyeloid-derived Suppressor CellsRenal Cell CarcinomaRenal NeoplasmsArginine MetabolismImmune Cell Cytokine ProductionMyeloid-derived Suppressor Cell FunctionMyeloid-derived Suppressor Cell MetabolismMyeloid-derived Suppressor Cell PhenotypeOverproduction Of ArginineRenal MalignancyT Cell Cytokine Production
Myeloid suppressor cells with high arginase activity are found in tumors and spleen of mice with colon and lung cancer. These cells, described as macrophages or immature dendritic cells, deplete arginine and impair T cell proliferation and cytokine production. Although arginase activity has been described in cancer patients, it is thought to originate from tumor cells metabolizing arginine to ornithine needed to sustain rapid cell proliferation. The goal of this study was to determine whether myeloid suppressor cells producing high arginase existed in renal cell carcinoma patients. Peripheral blood mononuclear cells from 123 patients with metastatic renal cell carcinoma, prior to treatment, were found to have a significantly increased arginase activity. These patients had a markedly decreased cytokine production and expressed low levels of T cell receptor CD3zeta chain. Cell separation studies showed that the increased arginase activity was limited to a specific subset of CD11b+, CD14-, CD15+ cells with a polymorphonuclear granulocyte morphology and markers, instead of macrophages or dendritic cells described in mouse models. Furthermore, these patients had low levels of arginine and high levels of ornithine in plasma. Depletion of the CD11b+, CD14- myeloid suppressor cells reestablished T cell proliferation and CD3zeta chain expression. These results showed, for the first time, the existence of suppressor myeloid cells producing arginase in human cancer patients. In addition, it supports the concept that blocking arginase may be an important step in the success of immunotherapy.
15
David F. McDermott, Meredith M. Regan, Joseph I. Clark et al. · Journal of Clinical Oncology · 2004 · 819 citations
Medicine, Oncology, Pharmacotherapy +15
IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice
Vincenzo Bronte, Paolo Serafini, Carmela De Santo et al. · The Journal of Immunology · 2003 · 505 citations · Full text